Table 1. EGFR TKIs in clinical use in the United States (3,8).

Name	Indications	Year of approval
First generation
Gefitinib	Second line for advanced or metastatic NSCLC (withdrawn)	2003
	First line in metastatic NSCLC with exon 19 (del) or exon 21 (L858R) mutations	2015
Erlotinib	First line and after progression on platinum chemotherapy for metastatic NSCLC with exon 19 (del) or exon 21 (L858R) mutations	2004
	Maintenance therapy in locally advanced metastatic disease	2010
Second generation
Afatinib	First line in metastatic disease harboring nonresistant EGFR mutations	2013
	Metastatic squamous NSCLC after progression on platinum-based therapy
Dacomitinib	First-line therapy for metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations	2018
Third generation
Osimertinib	Metastatic NSCLC with EGFR T790M who have progressed on, or after EGFR TKI therapy	2015
	First line in EGFR mutant advanced or metastatic disease	2018

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer.